Clinical Trials Logo

Healthy Study Participants clinical trials

View clinical trials related to Healthy Study Participants.

Filter by:

NCT ID: NCT06312566 Not yet recruiting - Clinical trials for Healthy Study Participants

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

Start date: April 22, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is to demonstrate the bioequivalence between the BRV tablet and BRV dry syrup after multiple oral doses in healthy male Japanese participants.

NCT ID: NCT05845645 Recruiting - Clinical trials for Healthy Study Participants

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

Start date: May 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to estimate the relative bioavailability of 2 new UCB0599 formulations under elevated and normal gastric pH conditions in healthy participants (Part A) and to asess the safety, tolerability and pharmacokinetics of UCB0599 in healthy participants of Japanese and Chinese origins (Part B).

NCT ID: NCT05315947 Completed - Clinical trials for Healthy Study Participants

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

Start date: April 4, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to demonstrate the bioequivalence between the BRV tablet and BRV as dry syrup after a single oral dose in healthy Japanese male study participants.

NCT ID: NCT05292131 Completed - Clinical trials for Healthy Study Participants

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Start date: March 17, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to compare the pharmacokinetics (PK), safety and tolerability of a single subcutaneous (sc) dose of bimekizumab (BKZ) when administered using bimekizumab-autoinjector (AI)-2mL presentation versus bimekizumab-AI-2x1mL presentation in healthy study participants.

NCT ID: NCT04867642 Completed - Parkinson's Disease Clinical Trials

A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

Start date: April 29, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of UCB0022 and food effect.

NCT ID: NCT04828343 Completed - Clinical trials for Healthy Study Participants

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

Start date: April 22, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single subcutaneous (SC) dose of rozanolixizumab administered to healthy participants by manual push (MP) versus (vs) syringe driver.

NCT ID: NCT04802746 Completed - Clinical trials for Healthy Study Participants

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

Start date: March 9, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the pulmonary safety of Staccato alprazolam in healthy study participants and in and study participants with mild asthma

NCT ID: NCT04782388 Completed - Clinical trials for Healthy Study Participants

Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

Start date: March 4, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of Staccato alprazolam in healthy Japanese, Chinese, and Caucasian participants.

NCT ID: NCT04705350 Completed - Clinical trials for Healthy Study Participants

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

Start date: January 11, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of zampilimab in healthy study participants.

NCT ID: NCT04444466 Terminated - Clinical trials for Chronic Spontaneous Urticaria

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants

Start date: June 30, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess safety, tolerability and pharmacokinetics (PK) of oral UCB8600.